Science
Waisman Biomanufacturing partners with GigaGen to manufacture new COVID-19 drug – Mirage News
Waisman Biomanufacturing at the University of Wisconsin-Madison will begin manufacturing a new drug to treat and prevent COVID-19, developed by…
Waisman Biomanufacturing at the University of Wisconsin-Madison will begin manufacturing a new drug to treat and prevent COVID-19, developed by California-based biotech company GigaGen.
The drug, called GIGA-2050, uses a new approach similar to treating COVID-19 patients with convalescent plasma, or blood products from people recovering (convalescing) from an infection. Waisman Biomanufacturing was created to facilitate just this sort of development and testing of new types of drugs.
“Our miss…
-
General22 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
General22 hours agoLithium mine closure shines light on Ravensthorpe community’s resilience
-
General24 hours agoBack-to-back rate cuts tipped when Reserve Bank meets
-
Noosa News23 hours agoWoman left with significant arm injuries in lion attack at Darling Downs Zoo in Queensland